October 2nd 2024
Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Pembrolizumab Receives Priority Review Designation from FDA for Frontline HNSCC
February 12th 2019Based on data from the phase III KEYNOTE-048 trial, pembrolizumab has received a priority review designation from the FDA alone or in combination with platinum and 5-fluorouracil chemotherapy as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Read More
Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCC
December 13th 2018The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.
Read More
No Survival Benefit Found With Durvalumab in Head and Neck Cancer
December 10th 2018AstraZeneca has reported that the phase III EAGLE trial has missed its primary endpoint, as patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy did not see a survival benefit with durvalumab alone or combined with tremelimumab.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
Promising Activity Seen With Palbociclib/Cetuximab Combo in HPV-Unrelated HNSCC
July 12th 2018An overall response rate of 39% was induced with the combination of the CDK4/6 inhibitor palbociclib and cetuximab in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.
Read More